# REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 Balance Sheet

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: As of 2026-03-31
- Filing: Q1 FY2026 10-Q, filed 2026-04-29, accession number 0000872589-26-000016
- Page: https://plicit.ai/financials/regn/fy2026-q1-balance-sheet
- Chart image: https://plicit.ai/charts/regn-fy2026-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 40,868,800,000 US dollars
- **Current assets**: 18,209,200,000 US dollars
- **Non-current assets**: 22,659,600,000 US dollars
- **Liabilities**: 9,445,200,000 US dollars
- **Current liabilities**: 5,107,700,000 US dollars
- **Non-current liabilities**: 4,337,500,000 US dollars
- **Equity**: 31,423,600,000 US dollars
- **Marketable securities**: 5,791,100,000 US dollars
- **Accounts receivable, net**: 5,731,000,000 US dollars
- **Inventories**: 3,103,600,000 US dollars
- **Cash and cash equivalents**: 2,962,600,000 US dollars
- **Prepaid expenses and other current assets**: 620,900,000 US dollars
- **Marketable securities**: 9,786,000,000 US dollars
- **Property, plant, and equipment, net**: 5,266,100,000 US dollars
- **Deferred tax assets**: 4,190,900,000 US dollars
- **Other noncurrent assets**: 2,129,700,000 US dollars
- **Intangible assets, net**: 1,286,900,000 US dollars
- **Accrued expenses and other current liabilities**: 2,724,400,000 US dollars
- **Accounts payable**: 1,027,100,000 US dollars
- **Finance lease liabilities**: 720,000,000 US dollars
- **Deferred revenue**: 636,200,000 US dollars
- **Other noncurrent liabilities**: 2,126,200,000 US dollars
- **Long-term debt**: 1,986,200,000 US dollars
- **Deferred revenue**: 225,100,000 US dollars
- **Finance lease liabilities**: 0 US dollars
- **Retained earnings**: 36,423,800,000 US dollars
- **Additional paid-in capital**: 14,401,300,000 US dollars
- **Accumulated other comprehensive income**: 11,900,000 US dollars
- **Common stock - Common Stock**: 100,000 US dollars
- **Common stock - Class A Stock**: 0 US dollars
- **Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none**: 0 US dollars
- **Treasury Stock, at cost; 34.7 shares in 2026 and 33.7 shares in 2025**: negative 19,413,500,000 US dollars
- **Gross equity (calculated)**: 50,837,100,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.